3Stoppa-Lyonnet D,Ansquer Y,Dreyfus H. Familial invasive breast cancers:worse outcome related to BRCA1 mutations[J].Clinical Oncology,2000,(24):4053-4059.
4Kennedy RD,Quinn JE,Mullan PB. The role of BRCA1 in the cellular response to chemotherapy[J].National Cancer Institute,2004,(22):1659-1668.
6Kreike B,van Kouwenhove M,Horlings H. Gene expression profiling and histopathological characterization of triple-negative basal-like breast carcinomas[J].Breast Cancer Research,2007,(05):R65.
7汤钊酞.现代肿瘤学[M]上海:上海医科大学出版社,2000110-111.
8李恩孝.恶性肿瘤分子靶向治疗[M]北京:人民卫生出版社,2011126-134.
9Clive S,Dixon JM. The value of adjuvant treatment in young women with breast cancer[J].Drugs,2002,(01):1-11.
5Colleoni M,Gelber S,Goldhirsch A,et al.Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph nodepositive breast cancer:International Breast Cancer Study Group Trial 13-93[J].J Clin Oncol,2006,24(9):1332-1341
6Pritchard KI,Shepherd LE,O'Malley FP,et al.HER2 and responsiveness of breast cancer to adjuvant chemotherapy[J].N Engl J Med,2006,354(20):2103-2111
7Piccart-Gebhart MJ,Procter M,Leyland-Jones B,et al.Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer[J].N Engl J Med,2005,353(16):1659-1672
8Sorlie T,Tibshirani R,Parker J,et al.Repeated observation of breast tumor subtypes in independent gene expression data sets[J].Proc Natl Acad Sci U S A,2003,100(14):8418-8423
9Nielsen TO,Hsu FD,Jeosen K,et al.Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma[J].Clin Cancer Res,2004,10(16):5367-5374
10Siziopikou KP,Cobleigh M.The basal subtype of breast carcinomas may represent the group of breast tumors that could benefit from EGFR-targeted therapies[J].Breast,2007,16(1):104-107
4Reis-Filho JS, Tutt AN. Triple negative tumours: a critical review. Histopatholog, 2008, 52(1 ): 108-118.
5Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA, 2005, 293(9) : 1073-1081.
6Kang SP, Martel M, Harris LN. Triple negative breast cancer: cur- rent under-stangding of biology and treatment options. Curr Opin Obster Gynecol, 2008, 20(1 ): 4046.
7Bauer KR, Brown M, Cress RD, et al. Descriptive analysis of estro- gen receptor ( ER ) -negative, progesterone receptor ( PR ) -negative, and HER2-negative invasive breast cancer, the so-called triple-nega- tive phenotype: a population-based study from the California cancer Registry. Cancer, 2007, 109(9) : 1721-1728.
8Yu KD, Li JJ, Di GH, et al. A straightforward but not piecewise rela- tionship between age and lymph node status in Chinese breast cancer patients. PLoS One, 2010, 5(6): e11035.
9Konigsberg R, Pfeiler G, Klement T, et al. Tumor characteristics and recurrence patterns in triple-negative breast cancer: a comparison between younger( < 65 ) and elderly (≥65 ) patients. Eur J Cancer, 2012, 48(16) : 2962-2968.
10Tisehkowitz M, Brunet JS, Begin LR, et al. Use of immunohisto- chemical markers can refine prognosis in triple negative breast cancer. BMC Cancer, 2007, 7: 134.
